Does Fifty410 Raise GLP-1 Prices When Your Dose Increases? — 2026

Last reviewed: September 16, 2026 Last updated: September 16, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

PlexusDx publishes this comparison and is one of the providers discussed. We use the same evidence rules for our own program and competing programs.

The short answer

It depends on the medication. Fifty410 publishes a single $199-per-month rate for compounded semaglutide injection—no price increase when your dose climbs. For compounded tirzepatide injection, Fifty410 operates three distinct dose tiers: starter dose costs $399 per 3-month cycle, mid dose $499 per 3-month cycle, and high dose $549 per 3-month cycle. Each tier ships a 3-month supply upfront and bills the full amount at the start of the cycle. Semaglutide patients pay one price from start to maintenance; tirzepatide patients step through progressively higher charges as their provider advances their dose.

Fifty410 pricing: one tier for semaglutide, three for tirzepatide

All figures verified September 4, 2026 from https://www.fifty410.com/pricing/semaglutide and https://www.fifty410.com/pricing/tirzepatide. Fifty410 includes the online provider consult, medication, and shipping in every price; the company charges no subscription or membership fee and describes its service as "pay only if prescribed" with no contract. Patients cancel or pause anytime.

The practical difference: a semaglutide patient moving from 0.5 mg weekly to 2.4 mg weekly pays the same $199 every month. A tirzepatide patient starting at 2.5 mg weekly and titrating to 12.5 mg weekly will see their 3-month charge rise from $399 to $499 and potentially to $549 as their provider advances the dose. Expressed as prepaid per-month equivalents—our calculation—the starter tier works out to $133 per month over three months, the mid tier to $166 per month, and the high tier to $183 per month. The patient pays the full 3-month amount upfront at the start of each cycle.

Fifty410 tirzepatide vs. PlexusDx: 12-month cost comparison

Dose-increase pricing matters most over a full titration cycle. The table below shows the 12-month cost of compounded tirzepatide injection at Fifty410 across its three tiers and at PlexusDx across its three plan lengths, all at like-for-like cadences. PlexusDx charges the same rate regardless of dose; a patient on 2.5 mg weekly and a patient on 15 mg weekly pay an identical monthly fee.

Twelve-month totals are our calculation: Fifty410 figures multiply the per-cycle charge by four cycles; PlexusDx figures multiply the monthly rate by twelve. Fifty410's tirzepatide pricing delivers a clear cost advantage for patients who reach and stay on higher doses—$2,196 annually at the high-dose tier versus $2,988 for PlexusDx's best 6-month rate. The advantage narrows or reverses if a patient remains on starter or mid doses for the full year, since PlexusDx holds the same price at every dose level. A patient who spends three months each on starter, mid, and high tiers, then stays on high dose for the final quarter, would pay $399 + $499 + $549 + $549 = $1,996 at Fifty410 over twelve months—still materially below PlexusDx's flat annual rates.

Decision factors: prepay cadence, upfront capital, and dose trajectory

Prepay cadence and cash flow. Fifty410's tirzepatide model requires the full 3-month charge upfront at the start of each cycle—$399, $499, or $549 depending on your dose tier—then ships the entire supply at once. Patients who prefer smaller, predictable monthly debits will find that option only in Fifty410's semaglutide program ($199 per month) or in monthly-billed alternatives like PlexusDx. A patient moving to the high-dose tier faces a $549 charge every three months; spreading that obligation across twelve $183 installments is not an option under Fifty410's published structure.

Dose trajectory and total cost. If your provider expects you to reach and maintain a high maintenance dose, Fifty410's tiered model delivers clear annual savings compared to flat-rate programs with higher per-month fees. A patient stable on 12.5 or 15 mg tirzepatide weekly will pay $2,196 annually at Fifty410's high-dose tier; the same patient would pay $2,988 on PlexusDx's 6-month plan or $3,228 on its 3-month plan. Conversely, if you start and stay on a low or mid dose—common for patients prioritizing tolerability or combining medication with intensive lifestyle intervention—the advantage shrinks. A patient who remains on starter dose for twelve months pays $1,596 at Fifty410, while PlexusDx's 6-month plan still costs $2,988; the gap is meaningful, but the percentage difference is smaller than at higher doses.

Semaglutide dose-neutral pricing. Fifty410's semaglutide program eliminates dose-tier complexity entirely: $199 per month from 0.25 mg weekly through 2.4 mg weekly, billed monthly with a 4-week supply shipped each cycle. For comparison, PlexusDx charges $189 per month on its month-to-month plan, $169 per month on its 3-month plan, and $149 per month on its 6-month plan—all dose-neutral as well. Over twelve months, Fifty410 semaglutide totals $2,388 (our calculation: $199 × 12), PlexusDx month-to-month totals $2,268, the 3-month plan $2,028, and the 6-month plan $1,788. The semaglutide comparison turns on per-month rate and commitment length, not dose tier.

Choose Fifty410 if…

You expect to reach and remain on a high tirzepatide maintenance dose, you can comfortably pay $549 every three months upfront, and you value the annual cost floor that Fifty410's tier structure provides. The provider's 4.8-star Trustpilot rating across 5,891 reviews (captured September 4, 2026 from the Fifty410 website) suggests consistent service execution. Fifty410 offers a strong fit for patients whose clinical picture points toward sustained high-dose therapy and who appreciate receiving a full quarterly supply in a single shipment.

Choose PlexusDx if…

You want one predictable monthly charge regardless of where your dose lands, you prefer smaller recurring debits over quarterly lump sums, or your dose trajectory remains uncertain. PlexusDx holds a 4.3-star Trustpilot rating with 79% of reviews at five stars and 83% at four stars or higher (verified September 9, 2026; trustpilot.com/review/plexusdx.com). The 6-month plan locks $249 per month for compounded tirzepatide injection—higher than Fifty410's high-dose tier on an annualized basis, but delivered as twelve identical charges with no tier transitions and no upfront capital requirement beyond the first month. PlexusDx works with licensed 503A compounding pharmacies and includes the provider visit, medication, and shipping in every plan price with no membership fee.

Methodology and freshness

All Fifty410 pricing verified September 4, 2026 from the provider's published semaglutide and tirzepatide pricing pages. PlexusDx pricing reflects the canonical rate card current as of September 16, 2026. Twelve-month cost figures, prepaid per-month equivalents, and like-for-like comparisons are our calculation, derived by multiplying published per-cycle or per-month rates by the appropriate number of billing periods. No promotional codes, discount arithmetic, or undocumented rates appear in this analysis. We recommend confirming current pricing, dose-tier definitions, and billing cadence at checkout, as telehealth providers update their commercial structures periodically.

Frequently Asked Questions

Does Fifty410 charge more when my semaglutide dose increases?

No. Fifty410 publishes a single $199-per-month rate for compounded semaglutide injection, regardless of dose. A patient on 0.5 mg weekly and a patient on 2.4 mg weekly pay the same monthly fee, and the price does not rise as your provider advances your dose during titration.

What are Fifty410's three tirzepatide dose tiers?

Fifty410 labels them starter dose ($399 per 3-month cycle), mid dose ($499 per 3-month cycle), and high dose ($549 per 3-month cycle). Each tier corresponds to a range of weekly milligram doses; your provider determines which tier fits your current prescription, and you pay the applicable tier rate upfront for the next three months of medication.

Can I pay Fifty410's tirzepatide charges monthly instead of every three months?

No. Fifty410's published tirzepatide structure requires the full 3-month charge upfront—$399, $499, or $549 depending on your dose tier—and ships the entire supply at once. Monthly billing is available only for Fifty410's semaglutide program. Patients seeking smaller recurring debits for tirzepatide will need to compare providers that bill monthly.

How much do I save with Fifty410's high-dose tirzepatide tier versus a flat-rate program?

Fifty410's high-dose tier costs $2,196 annually (our calculation: $549 per cycle × 4 cycles). PlexusDx's 6-month tirzepatide plan, which holds the same $249 monthly rate at every dose, totals $2,988 annually (our calculation: $249 × 12). The difference is $792 per year in favor of Fifty410, assuming you remain on the high-dose tier for all twelve months.

Are Fifty410's compounded semaglutide and tirzepatide FDA-approved?

No. Compounded medications are not FDA-approved. FDA does not review compounded drugs before marketing for safety, effectiveness, or quality. A licensed clinician determines whether a prescription is appropriate for an individual patient. Fifty410's medications are compounded; they are not the same as branded GLP-1 drugs like Ozempic or Mounjaro.

Sources

• Fifty410 semaglutide pricing page, https://www.fifty410.com/pricing/semaglutide, accessed September 4, 2026.
• Fifty410 tirzepatide pricing page, https://www.fifty410.com/pricing/tirzepatide, accessed September 4, 2026.
• Fifty410 Trustpilot rating, captured from provider website September 4, 2026.
• PlexusDx Trustpilot profile, https://www.trustpilot.com/review/plexusdx.com, accessed September 9, 2026.
• PlexusDx canonical pricing, internal rate card current as of September 16, 2026.

Compounded medication disclosure: Compounded medications are not FDA-approved. FDA does not review compounded drugs before marketing for safety, effectiveness, or quality. A licensed clinician determines whether a prescription is appropriate for an individual patient. PlexusDx works with licensed 503A compounding pharmacies.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.